Trump Administration Withdraws on Fighting for NIH Cap on Indirect Costs

Why It Matters

The decision preserves existing overhead rates, protecting billions of dollars of university research funding and maintaining financial stability for U.S. labs. It also shifts the focus of indirect‑cost reform to legislative and policy avenues rather than court‑driven caps.

Key Takeaways

• NIH's 15% indirect-cost cap blocked, costing $6.5B
• Trump admin missed Supreme Court petition deadline, ending litigation
• Appeals court ruled cap unlawful, violating HHS and 2017 appropriations
• AAMC pushes FAIR model for transparent indirect-cost accounting

Pulse Analysis

The indirect‑cost rate—often called overhead—has long been a financial linchpin for U.S. research universities. Historically, institutions negotiate rates ranging from 30 % to 70 % to cover facility maintenance, utilities, and administrative support. In February 2025, the National Institutes of Health announced a dramatic reduction to a flat 15 % cap, a move projected to strip the research enterprise of roughly $6.5 billion in reimbursable expenses. Proponents argued the cut would curb wasteful spending, while critics warned it would jeopardize the operational stability of labs that rely on higher overhead recoveries.

The policy quickly attracted legal challenges from state attorneys general, the Association of American Medical Colleges and dozens of universities. A federal appeals court affirmed a district‑court injunction, declaring the 15 % cap unlawful because it contravened Department of Health and Human Services regulations and a 2017 congressional appropriations provision. The Trump administration had a 90‑day window to petition the Supreme Court, but the deadline lapsed without action, effectively closing the litigation. Similar withdrawals occurred in parallel cases involving the Department of Energy, NSF, and the Department of Defense, signaling a broader retreat.

With the court’s decision standing, the debate over indirect‑cost transparency has shifted to Congress and agency guidance. The Association of American Medical Colleges is championing the Financial Accountability in Research (FAIR) model, which aims to standardize reporting and improve taxpayer visibility. Meanwhile, an August executive order still encourages federal agencies to favor institutions with lower overhead rates, suggesting indirect‑cost reform may continue through funding preferences rather than statutory caps. Stakeholders will watch closely how legislative proposals and agency policies evolve, as the outcome will shape the fiscal health of America’s research ecosystem.